Interleuchina-8 (IL-8), also known as CXCL8, is a crucial chemokine involved in the regulation of immune and inflammatory responses. As a member of the cytokine family, IL-8 functions primarily as a chemoattractant, directing the migration of immune cells—especially neutrophils—to sites of infection, tissue damage, or inflammation. It exerts its effects by binding to two G-protein-coupled receptors, CXCR1 and CXCR2, which are expressed on the surface of neutrophils and other immune cells, initiating intracellular signaling pathways such as PI3K/AKT, MAPK/ERK, and NF-κB. IL-8 is produced by various cell types, including macrophages, endothelial cells, and epithelial cells, in response to pro-inflammatory stimuli like TNF-α and IL-1. Its role extends beyond acute inflammation, as dysregulated IL-8 expression contributes to chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and respiratory conditions like COPD. Furthermore, IL-8 plays a significant role in cancer progression by promoting angiogenesis, metastasis, and tumor microenvironment immunosuppression through the recruitment of tumor-associated neutrophils and MDSCs. Due to its central role in inflammation and cancer, IL-8 is being investigated as a potential biomarker and therapeutic target, with inhibitors of IL-8 and its receptors currently in clinical development [1][2].

Molecular Structure and Isoforms of IL-8

Interleukina-8 (IL-8), also known as CXCL8, is a member of the CXC chemokine family, characterized by a conserved structural motif that includes two cysteine residues separated by one amino acid (C-X-C). The mature, biologically active form of IL-8 is typically composed of 72 amino acids (IL-8(7–77)), derived from a 99-amino acid precursor (prepro-IL-8) through post-translational processing [3]. This processing involves the removal of a 27-amino acid signal peptide in the endoplasmic reticulum and subsequent cleavage of an N-terminal pro-sequence to yield the active chemokine [3].

Three-Dimensional Structure and Dimerization

The three-dimensional structure of IL-8 has been elucidated primarily through nuclear magnetic resonance (NMR) spectroscopy in solution. IL-8 can exist as a monomer or a homodimer, but the dimeric form predominates at physiological concentrations [5]. The dimer is stabilized by hydrophobic interactions between the helical regions of two subunits and by conserved disulfide bonds typical of CXC chemokines [5]. Each subunit of the dimer features a characteristic fold consisting of an N-terminal β-hairpin loop (N-loop), followed by two antiparallel α-helices arranged into a stable helical bundle [5]. Residues such as Glu4 and Leu25 are involved in dimer stabilization, while the N-terminal domain (residues 1–9) is critical for receptor activation [8]. The dimeric structure may enhance the stability of IL-8 in the extracellular environment and modulate its interaction with glycosaminoglycans (GAGs) on endothelial surfaces, which is essential for establishing chemotactic gradients [9].

Monomeric Function and Receptor Binding

Despite the prevalence of the dimer, the monomeric form of IL-8 is biologically active and sufficient to activate neutrophils [8]. The receptor-binding mechanism follows a two-step model: first, the N-loop of IL-8 docks with the extracellular domain of its receptors, CXCR1 and CXCR2, and then the N-terminus of the chemokine inserts into the transmembrane cavity of the receptor, inducing a conformational change necessary for G-protein activation [3]. The monomer is particularly effective in this interaction, especially with CXCR1, whereas CXCR2 can be activated by both monomeric and dimeric forms [12].

Post-Translational Modifications and Proteolytic Processing

The functional diversity of IL-8 is further expanded by post-translational modifications and proteolytic processing. Enzymes such as neutrophil elastase, cathepsin G, and proteinase-3 can cleave the N-terminus of IL-8, generating truncated isoforms like IL-8(6–77) or IL-8(7–77) [13]. These truncated forms exhibit altered receptor affinity and signaling properties; for instance, they may show enhanced potency in inducing receptor internalization and chemotaxis while reducing receptor desensitization, thereby prolonging neutrophil recruitment [14]. Additionally, citrullination, a modification catalyzed by peptidylarginine deiminases (PADs), alters the charge of IL-8 and can modulate its interaction with CXCR1 and CXCR2, potentially increasing its signaling efficiency [15].

Functional Differences Among Isoforms

The various isoforms of IL-8, generated through proteolytic cleavage or post-translational modifications, display distinct functional profiles. Truncated isoforms often exhibit increased chemotactic potency for neutrophils and enhanced ability to induce receptor internalization compared to the full-length form [16]. For example, CXCL8(6–77) shows a greater capacity to induce internalization of both CXCR1 and CXCR2, suggesting more efficient receptor activation [15]. These isoforms can differentially regulate neutrophil functions: CXCR1 activation is more associated with respiratory burst and degranulation via NADPH oxidase and phospholipase D activation, while CXCR2 is more involved in cell migration and proliferation [18]. Thus, the spectrum of IL-8 isoforms allows for fine-tuned regulation of neutrophil responses in both physiological and pathological contexts.

Bacterial Evasion and Pathological Implications

The proteolytic regulation of IL-8 is not only a physiological control mechanism but also a target for pathogenic evasion. Bacterial proteases, such as SpyCEP (ScpC) from Streptococcus pyogenes, specifically cleave and inactivate IL-8, thereby impairing neutrophil recruitment and facilitating immune evasion and bacterial virulence [19]. This highlights the critical role of IL-8 integrity in host defense. In pathological conditions such as chronic inflammation or cancer, an imbalance between IL-8 production and degradation can lead to dysregulated neutrophil activity, contributing to tissue damage or tumor progression [20]. The presence of specific IL-8 proteoforms in biological fluids may serve as potential biomarkers for disease activity or prognosis [14].

Receptors and Signaling Pathways

Interleuchina-8 (IL-8), also known as CXCL8, exerts its biological effects primarily by binding to two high-affinity receptors on the surface of target cells: CXCR1 and CXCR2. These receptors belong to the family of G protein-coupled receptors (GPCRs), a large group of membrane proteins that transduce extracellular signals into intracellular responses [22]. CXCR1 and CXCR2 are predominantly expressed on neutrophils, but are also found on monocytes, macrophages, endothelial cells, and certain tumor cells, enabling IL-8 to regulate diverse physiological and pathological processes [23].

Receptor Specificity and Ligand Binding

CXCR1 and CXCR2 exhibit distinct ligand-binding profiles, which contribute to their specialized functions. CXCR1 demonstrates high specificity, binding primarily to IL-8 (CXCL8) and, to a lesser extent, to CXCL6 (GCP-2) [24]. In contrast, CXCR2 is a promiscuous receptor, capable of interacting with multiple ELR+ CXC chemokines, including CXCL1 (GRO-α), CXCL2 (GRO-β), CXCL3 (GRO-γ), CXCL5 (ENA-78), CXCL7 (NAP-2), and CXCL8 (IL-8) [25]. This difference in ligand specificity allows CXCR2 to integrate a broader range of chemotactic signals, making it a central hub for neutrophil recruitment in response to various inflammatory stimuli.

The binding of IL-8 to its receptors follows a two-step model. Initially, the N-loop domain of IL-8 docks with the extracellular N-terminus of the receptor. This is followed by the insertion of the N-terminal residues of IL-8 into the transmembrane pocket of CXCR1 or CXCR2, triggering a conformational change that activates the associated G protein [3]. The structural basis for this interaction involves key residues in the N-terminal region of IL-8, such as Glu4 and Leu25, which are critical for dimer stability and receptor activation [5].

Intracellular Signaling Mechanisms

The activation of CXCR1 and CXCR2 by IL-8 initiates a complex cascade of intracellular signaling events, primarily mediated by the dissociation of the heterotrimeric G protein into its α and βγ subunits. The Gαi subunit inhibits adenylate cyclase, reducing intracellular levels of cyclic AMP (cAMP), while the Gβγ subunit activates several downstream effector pathways that regulate neutrophil function.

One of the earliest signaling events is the activation of phospholipase C (PLC), particularly the PLCβ isoform. PLC hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP₂) into inositol 1,4,5-trisphosphate (IP₃) and diacylglycerol (DAG). IP₃ binds to receptors on the endoplasmic reticulum, triggering a rapid release of intracellular calcium (Ca²⁺) [28]. This calcium flux is a critical signal for neutrophil activation, regulating processes such as degranulation, the respiratory burst, and cytoskeletal reorganization [29].

Key Signaling Pathways Regulating Neutrophil Function

The biological effects of IL-8, particularly chemotaxis and cellular activation, are orchestrated by several major signaling pathways:

  1. PI3K/AKT Pathway: The Gβγ subunit activates phosphoinositide 3-kinase (PI3K), which phosphorylates PIP₂ to generate phosphatidylinositol (3,4,5)-trisphosphate (PIP₃). PIP₃ serves as a docking site for proteins with pleckstrin homology (PH) domains, such as Akt (PKB) [30]. This pathway is essential for establishing cell polarity and directing actin polymerization at the leading edge of migrating neutrophils, thereby enabling chemotaxis along the IL-8 gradient [31].

  2. MAPK Pathway: IL-8 activates multiple branches of the mitogen-activated protein kinase (MAPK) family:

    • ERK1/2 (Extracellular signal-Regulated Kinases): Activated via the Ras-Raf-MEK-ERK cascade, ERK1/2 is involved in cell proliferation, adhesion, and chemotaxis [32].
    • p38 MAPK: This kinase responds to stress and inflammatory cytokines, regulating the production of other cytokines, degranulation, and cell survival [33].
    • JNK (c-Jun N-terminal Kinase): While less studied in neutrophils, JNK contributes to apoptosis and inflammatory responses.

  3. NF-κB Pathway: IL-8 can activate the nuclear factor kappa B (NF-κB) pathway, often through upstream kinases like IKK, which leads to the degradation of IκB and the nuclear translocation of NF-κB [34]. NF-κB regulates the transcription of genes involved in inflammation, including IL8 itself, creating a positive feedback loop that amplifies the inflammatory response [35].

  4. Rho GTPase Pathway: The activation of small GTPases such as rac, cdc42, and rhoA is crucial for cytoskeletal dynamics. Rac and Cdc42 promote actin polymerization and the formation of lamellipodia and filopodia at the cell front, while RhoA regulates actomyosin contractility at the rear, facilitating forward movement [36].

Functional Differences Between CXCR1 and CXCR2

Despite their structural similarities, CXCR1 and CXCR2 mediate distinct aspects of the neutrophil response. CXCR2 is primarily responsible for the initial recruitment and migration of neutrophils from the bloodstream into inflamed tissues. Its rapid internalization and recycling make it highly effective in guiding cell trafficking during the early phases of acute inflammation [37]. In contrast, CXCR1 is more involved in the terminal activation of neutrophils once they reach the site of inflammation. It plays a key role in processes such as degranulation, the release of lysosomal enzymes, the generation of the oxidative burst, and the formation of neutrophil extracellular traps (NETs) [38].

This functional specialization means that CXCR2 drives the bulk of neutrophil influx, while CXCR1 enhances the microbicidal and cytotoxic capabilities of the recruited cells. The differential signaling is reflected in their coupling to intracellular pathways; CXCR2 is more strongly linked to the activation of Akt and the MAPK pathway, which regulate migration and survival, whereas CXCR1 is particularly efficient at inducing intracellular calcium release and activating enzymes involved in reactive oxygen species (ROS) production [36].

Regulation of Receptor Activity

To prevent excessive and damaging inflammation, the activity of CXCR1 and CXCR2 is tightly regulated. After activation, the receptors are phosphorylated by G protein-coupled receptor kinases (GRKs), which promotes the binding of arrestin proteins. This process, known as desensitization, uncouples the receptor from its G protein and targets it for internalization via endocytosis [40]. This mechanism ensures that the neutrophil response is transient and spatially controlled, allowing the cell to adapt to changing chemokine gradients.

Regulation of IL-8 Expression

The expression of interleukin-8 (IL-8), also known as CXCL8, is tightly regulated through a complex network of transcriptional and post-transcriptional mechanisms activated by pro-inflammatory stimuli. This regulation is essential for orchestrating the recruitment of immune cells, particularly neutrophils, to sites of infection, tissue damage, or chronic inflammation. The precise control of IL-8 levels ensures an effective yet balanced immune response, preventing excessive or prolonged inflammation that could lead to tissue injury and disease progression.

Transcriptional Regulation by Key Transcription Factors

The primary mechanism controlling IL-8 expression occurs at the transcriptional level, where specific transcription factors bind to the promoter region of the IL8 gene in response to inflammatory signals. Three major transcription factors play central roles: NF-κB, AP-1, and C/EBPβ.

  • NF-κB (Nuclear Factor kappa B): This is the most critical regulator of IL-8 expression. In response to stimuli such as TNF-α, IL-1, or bacterial components like LPS, the inhibitor IκBα is phosphorylated and degraded, allowing NF-κB (typically a p65/p50 heterodimer) to translocate into the nucleus. There, it binds to specific κB sites in the IL8 promoter, initiating transcription [41]. The activation of NF-κB is indispensable for the rapid upregulation of IL-8 during both acute and chronic inflammation.

  • AP-1 (Activator Protein-1): Formed by dimers of proteins from the Fos and Jun families, AP-1 is activated by MAPK signaling pathways, including p38 and JNK, in response to stress or cytokine exposure. AP-1 binds to its cognate site in the IL8 promoter and acts synergistically with NF-κB to maximize gene expression [42].

  • C/EBPβ (CCAAT/enhancer-binding protein beta): Also known as NF-IL6, this transcription factor cooperates with both NF-κB and AP-1 to enhance IL-8 production. It is particularly important in epithelial and monocytic cells, where it contributes to the sustained expression of IL-8 during prolonged inflammatory states [43].

The cooperative interaction among NF-κB, AP-1, and C/EBPβ creates a robust transcriptional complex that allows for a rapid and amplified response to inflammatory cues, ensuring high-level production of IL-8 when needed.

Regulation in Acute vs. Chronic Inflammation

The regulation of IL-8 differs significantly between acute and chronic inflammatory conditions, reflecting the distinct biological needs of each context.

  • Acute Inflammation: During acute responses, IL-8 expression is rapidly induced in cells such as macrophages, endothelial cells, and epithelial cells upon detection of pathogens or tissue injury. This swift induction, mediated by the activation of NF-κB and MAPK pathways via receptors like TLR4 and IL-1R, facilitates the immediate recruitment of neutrophils to eliminate invading microbes and initiate tissue repair [2].

  • Chronic Inflammation: In contrast, persistent or dysregulated activation of these same transcriptional pathways leads to sustained overexpression of IL-8. This is observed in diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. A positive feedback loop can develop where IL-8 itself activates NF-κB in certain cell types, further amplifying its own production and that of other pro-inflammatory mediators [45]. Additionally, epigenetic modifications such as histone H3 acetylation have been linked to enhanced IL8 gene accessibility and prolonged expression in inflamed tissues [46].

Post-Translational and Proteolytic Regulation

Beyond transcriptional control, IL-8 activity is modulated post-translationally, particularly through proteolytic processing. Enzymes such as neutrophil elastase, cathepsin G, and proteinase-3—released by activated neutrophils—can cleave the N-terminus of IL-8, generating truncated forms (e.g., IL-8(6–77)). These modified isoforms often exhibit altered receptor affinity and functional potency, sometimes enhancing chemotactic activity while reducing receptor desensitization, thereby prolonging neutrophil recruitment [13].

Moreover, bacterial proteases like SpyCEP from Streptococcus pyogenes can inactivate IL-8 as an immune evasion strategy, highlighting the evolutionary significance of this chemokine in host defense [19].

Modulation by Natural and Therapeutic Inhibitors

The expression and activity of IL-8 are also subject to negative regulation by endogenous and pharmacological agents. Natural compounds such as resveratrol and curcumin inhibit IL-8 production by suppressing NF-κB and MAPK signaling pathways [49]. Similarly, the plant-derived compound triptolide has been shown to suppress IL-1β-induced IL-8 expression, suggesting therapeutic potential in chronic inflammatory disorders [50].

In clinical settings, drugs like methotrexate, used in rheumatoid arthritis, reduce IL-8 levels in synovial fluid, contributing to their anti-inflammatory effects [51].

In summary, the expression of IL-8 is finely tuned by a combination of transcriptional activation, epigenetic modifications, and post-translational processing. The interplay of NF-κB, AP-1, and C/EBPβ ensures a rapid and robust response to danger signals, while regulatory mechanisms prevent uncontrolled inflammation. Dysregulation of this system contributes to chronic inflammatory and neoplastic diseases, making the pathways controlling IL-8 expression attractive targets for therapeutic intervention.

Role in Neutrophil Recruitment and Activation

Interleukin-8 (IL-8), also known as CXCL8, plays a central role in orchestrating the recruitment and activation of neutrophils, the most abundant type of white blood cell and a key component of the innate immune system. As a potent chemokine, IL-8 functions primarily as a chemoattractant, guiding neutrophils from the bloodstream to sites of infection, tissue injury, or inflammation. This process is critical for the early defense against pathogens, particularly bacteria and fungi, and is a hallmark of acute inflammatory responses [1].

The biological effects of IL-8 are mediated through its interaction with two specific G protein-coupled receptors, CXCR1 and CXCR2, which are highly expressed on the surface of neutrophils. The binding of IL-8 to these receptors initiates a cascade of intracellular signaling events that coordinate the complex, multi-step process of neutrophil migration and functional activation. This includes the initial rolling and firm adhesion of neutrophils to the vascular endothelium, followed by their transmigration (extravasation) into the inflamed tissue, and culminating in their activation to destroy invading microorganisms [53].

Chemotaxis and Leukocyte Extravasation

The primary function of IL-8 is to induce chemotaxis, the directed movement of neutrophils along a concentration gradient of the chemokine. This gradient is established when cells at the site of inflammation, such as macrophages, endothelial cells, and epithelial cells, produce and secrete IL-8 in response to pro-inflammatory stimuli like TNF-α, IL-1, or bacterial lipopolysaccharides (LPS) [54]. The IL-8 gradient guides the neutrophils from the circulation toward the source of the signal.

This process is a key component of leukocyte extravasation. IL-8, presented on the luminal surface of activated endothelial cells by binding to glycosaminoglycans (GAGs), triggers the firm adhesion of neutrophils by activating integrins on their surface. This strong adhesion allows the neutrophils to resist the shear forces of blood flow and to crawl along the endothelium. Subsequently, IL-8 stimulates the neutrophils to migrate between or through the endothelial cells (diapedesis) and into the underlying tissue. This entire sequence of events—rolling, adhesion, and transmigration—is essential for the rapid accumulation of neutrophils at the site of infection or injury [53].

Neutrophil Activation and Functional Responses

Beyond guiding their migration, IL-8 is a critical activator of neutrophil function. Once neutrophils reach the inflamed tissue, IL-8 "primes" them, enhancing their responsiveness to other stimuli and triggering a range of antimicrobial activities. The activation of CXCR1 and CXCR2 by IL-8 initiates several key intracellular signaling pathways, including the phospholipase C (PLC) pathway, which leads to the release of intracellular calcium (Ca²⁺). This calcium flux is a crucial second messenger that regulates numerous cellular processes [28].

One of the most important outcomes of IL-8-induced activation is the degranulation of neutrophils. This involves the release of pre-formed enzymes and antimicrobial proteins stored in granules, such as elastase, myeloperoxidase, and defensins, which are essential for killing and degrading pathogens. IL-8 also potently stimulates the oxidative burst, a process where the neutrophil produces high levels of reactive oxygen species (ROS), such as superoxide anion and hydrogen peroxide, through the activation of the NADPH oxidase complex. This oxidative burst is a primary mechanism for microbial killing [57].

Furthermore, IL-8 can promote the formation of neutrophil extracellular traps (NETs), web-like structures composed of DNA and antimicrobial proteins that trap and kill pathogens extracellularly. This activation also includes the upregulation of adhesion molecules and the production of additional cytokines, amplifying the inflammatory response. The signaling pathways involved in these processes include the PI3K/AKT pathway, which is vital for cell polarization and directional migration, and the MAPK/ERK pathway, which regulates degranulation and cytokine production [30].

Functional Differences Between CXCR1 and CXCR2

While both CXCR1 and CXCR2 are activated by IL-8, they play distinct and complementary roles in neutrophil biology. CXCR2 is more promiscuous, binding not only IL-8 but also other ELR+ CXC chemokines like CXCL1, CXCL2, and CXCL5. It is primarily responsible for the initial chemotaxis and recruitment of neutrophils from the bloodstream, due to its rapid internalization and recycling after ligand binding [59]. In contrast, CXCR1 has a higher specificity for IL-8 and is more involved in the terminal activation of neutrophils. It plays a key role in processes such as degranulation, the release of lysosomal enzymes, and the formation of NETs [8]. This functional division allows for a coordinated response: CXCR2 brings the neutrophils to the site, and CXCR1 ensures they are fully activated to perform their effector functions.

In summary, IL-8 is a master regulator of neutrophil-driven inflammation. Its ability to recruit neutrophils via chemotaxis and extravasation, coupled with its power to activate their antimicrobial arsenal through degranulation, oxidative burst, and NET formation, makes it indispensable for host defense. The differential signaling through CXCR1 and CXCR2 ensures a precise and effective immune response. However, dysregulation of this pathway, leading to excessive or prolonged neutrophil activation, can contribute to tissue damage and is a key factor in the pathogenesis of various chronic inflammatory diseases [1].

Involvement in Chronic Inflammatory Diseases

Interleukin-8 (IL-8), also known as CXCL8, plays a central role in the pathogenesis of various chronic inflammatory diseases by driving persistent neutrophil recruitment and activation, thereby perpetuating tissue damage and inflammation. As a potent chemokine, IL-8 is produced in response to pro-inflammatory stimuli such as TNF-α, IL-1, and microbial components like lipopolysaccharide (LPS), and acts primarily through its receptors CXCR1 and CXCR2 on neutrophils. While essential for acute host defense, dysregulated or sustained IL-8 expression contributes to the chronicity and progression of several autoimmune and inflammatory conditions.

Role in Specific Chronic Inflammatory Conditions

Elevated levels of IL-8 have been consistently observed in multiple chronic inflammatory disorders, where it functions as a key mediator of neutrophil infiltration and tissue destruction. In arthritis reumatoide (AR), IL-8 is abundantly produced by activated macrophages, synovial fibroblasts, and endothelial cells within the inflamed joint. High concentrations of IL-8 are detected in synovial fluid, where they drive the recruitment of neutrophils into the joint space. These infiltrating neutrophils release proteolytic enzymes such as elastase and collagenase, along with reactive oxygen species (ROS), which contribute directly to cartilage degradation and bone erosion. Furthermore, IL-8 promotes angiogenesis in the synovium, supporting the formation of invasive pannus tissue. The neutrophil-to-lymphocyte ratio (NLR), which reflects innate immune activation, correlates with IL-8 levels and disease activity, suggesting a role for IL-8 as both a pathogenic driver and a potential biomarker in AR.

In malattie infiammatorie intestinali (IBD), including Crohn's disease and ulcerative colitis, IL-8 is overexpressed in the intestinal mucosa. It is secreted by epithelial cells, lamina propria macrophages, and dendritic cells in response to luminal bacteria and inflammatory cytokines. Activation of the NF-κB pathway, often triggered by bacterial LPS, induces robust IL-8 expression, which in turn recruits neutrophils to the intestinal tissue. These activated neutrophils exacerbate mucosal damage by releasing myeloperoxidase, elastase, and neutrophil extracellular traps (NETs), leading to ulceration and barrier dysfunction. Clinical studies show that mucosal and systemic IL-8 levels correlate with endoscopic and clinical disease severity in active ulcerative colitis, although serum levels may not always accurately reflect local inflammation due to compartmentalization.

In psoriasi, a chronic autoimmune skin disorder, keratinocytes stimulated by cytokines such as IL-17 produce high levels of IL-8. This chemokine recruits neutrophils into the dermal papillae, contributing to the formation of Munro microabscesses, a hallmark histological feature of psoriatic plaques. The IL-8-mediated crosstalk between Th17 cells and neutrophilic inflammation underscores its role in linking adaptive and innate immune responses in the skin. Although serum IL-8 levels are elevated in psoriasis patients, their correlation with disease severity measured by the Psoriasis Area and Severity Index (PASI) is inconsistent, limiting its utility as a standalone systemic biomarker.

In broncopneumopatia cronica ostruttiva (BPCO), IL-8 is a major mediator of airway inflammation. Produced by alveolar macrophages and airway epithelial cells in response to cigarette smoke and pollutants, IL-8 drives the accumulation of neutrophils and macrophages in the lung parenchyma. This persistent neutrophilic inflammation leads to tissue remodeling, mucus hypersecretion, and elastin degradation via neutrophil elastase, contributing to emphysema and airflow obstruction. IL-8 levels in sputum and serum rise further during acute exacerbations, reflecting heightened inflammatory activity. However, while IL-8 is a biologically relevant marker of neutrophilic inflammation in BPCO, its correlation with long-term clinical outcomes such as survival or lung function decline remains weak, and it is not routinely used in clinical practice.

Mechanisms of Inflammation Perpetuation

The chronicity of inflammation in these diseases is sustained by a self-amplifying loop involving IL-8. Activated neutrophils themselves release additional IL-8 and other pro-inflammatory mediators such as IL-1β and TNF-α, which further stimulate IL-8 production by resident and infiltrating cells. This positive feedback loop, often reinforced by persistent activation of transcription factors like NF-κB, AP-1, and C/EBPβ, ensures continuous chemokine expression and neutrophil recruitment. Moreover, IL-8 contributes to angiogenesis and cellular survival, promoting the maintenance of inflammatory lesions. In some contexts, IL-8 can even act as an autoantigen, stimulating the production of anti-IL-8 autoantibodies and immune complexes that may exacerbate the inflammatory response, particularly in rheumatoid arthritis.

Therapeutic Implications and Biomarker Potential

Given its pivotal role in chronic inflammation, the IL-8 pathway represents a promising therapeutic target. Strategies under investigation include neutralizing antibodies against IL-8, such as BMS-986253 (HuMax-IL8), and small-molecule antagonists of CXCR1 and CXCR2, including reparixin, ladrarixin, and navarixin. These agents aim to disrupt neutrophil recruitment and activation, potentially reducing tissue damage. In preclinical and early clinical studies, CXCR1/2 inhibitors have shown efficacy in reducing inflammation in models of arthritis, colitis, and lung disease. However, no IL-8-targeted therapy has yet been approved for routine clinical use in chronic inflammatory diseases, partly due to concerns about increased susceptibility to infections from impaired neutrophil function.

As a biomarker, IL-8 holds promise but faces limitations. While elevated IL-8 levels correlate with disease activity in IBD and rheumatoid arthritis, its lack of specificity—being elevated in infections, other inflammatory conditions, and cancers—reduces its diagnostic value. Additionally, the absence of standardized assays and reference ranges hinders its clinical application. Nevertheless, IL-8 may serve as a useful component of multimodal biomarker panels or as a pharmacodynamic marker to assess target engagement in clinical trials of anti-inflammatory therapies.

Role in Cancer and Tumor Microenvironment

Interleukin-8 (IL-8), also known as CXCL8, plays a pivotal role in the development and progression of various cancers by shaping a pro-tumorigenic tumor microenvironment. Its overexpression is frequently observed in solid tumors, including those of the lung, colon, breast, pancreas, and melanoma, where it contributes to tumor growth, invasion, metastasis, and immune evasion [62]. The multifaceted actions of IL-8 in cancer are mediated through its interaction with the G-protein-coupled receptors CXCR1 and CXCR2, which are expressed not only on immune cells but also on tumor cells and endothelial cells, enabling autocrine and paracrine signaling loops that drive malignancy [63].

Promotion of Angiogenesis

One of the key mechanisms by which IL-8 supports tumor progression is through the stimulation of angiogenesis. By binding to CXCR1 and CXCR2 on endothelial cells, IL-8 activates intracellular signaling pathways such as PI3K/AKT and MAPK/ERK, which promote endothelial cell proliferation, migration, and survival [64]. This leads to the formation of new blood vessels that supply oxygen and nutrients to the growing tumor, facilitating its expansion. Experimental models have demonstrated that forced expression of IL-8 in gastric carcinoma cells significantly enhances tumor vascularization and growth in nude mice, confirming its direct pro-angiogenic role [65]. Consequently, the IL-8/CXCR1/2 axis is considered a critical target for anti-angiogenic therapy in oncology.

Facilitation of Tumor Cell Migration and Metastasis

IL-8 is a potent driver of tumor cell migration, invasion, and metastasis. It promotes the epithelial-mesenchymal transition (EMT), a process that endows cancer cells with migratory and invasive properties, by activating signaling cascades such as Wnt/β-catenin and MAPK [66]. In colorectal cancer, overexpression of IL-8 has been linked to increased cell motility, invasiveness, and metastatic potential [67]. Furthermore, IL-8 acts as an autocrine growth factor for many tumor cells, directly stimulating their proliferation and survival. The chemotactic gradient established by IL-8 also guides circulating tumor cells to distant organs, aiding in the formation of metastatic niches in sites such as the liver, lungs, and bones [68].

Induction of Immunosuppression

A critical function of IL-8 in the tumor microenvironment is the induction of immunosuppression, which allows cancer cells to evade immune surveillance. IL-8 recruits and activates immunosuppressive myeloid cells, particularly myeloid-derived suppressor cells (MDSCs) and tumor-associated neutrophils (TANs), which express CXCR1 and CXCR2 [69]. Once infiltrated into the tumor, these cells suppress the activity of cytotoxic T cells, inhibit lymphocyte proliferation, and promote the differentiation of regulatory T cells (Tregs), thereby dampening the anti-tumor immune response [70]. In lung cancer, high levels of IL-8 correlate with increased TAN infiltration and poor prognosis [71]. Additionally, IL-8 contributes to the polarization of macrophages toward the M2 phenotype, which further supports tumor growth and immune evasion [72].

Interaction with Myeloid Cells and Molecular Pathways

The crosstalk between tumor cells and myeloid cells under the influence of IL-8 involves several key molecular pathways. The NF-κB pathway is central to this interaction, as IL-8 activates NF-κB in both tumor and immune cells, leading to the expression of pro-inflammatory and pro-survival genes [45]. This creates a positive feedback loop, as NF-κB also upregulates IL-8 expression, amplifying the inflammatory and immunosuppressive signals. Another important pathway is the activation of focal adhesion kinase (FAK), which enhances tumor cell motility and invasion [74]. The IL-8/CXCR1/2 axis also regulates the formation of neutrophil extracellular traps (NETs), which can promote genomic instability, angiogenesis, and metastasis [75].

Prognostic and Predictive Biomarker

Elevated levels of IL-8 in serum or tumor tissue are consistently associated with poor prognosis across multiple cancer types, making it a valuable biomarker for disease severity and outcome [76]. High IL-8 expression correlates with reduced progression-free survival (PFS) and overall survival (OS) in patients with advanced cancers, including breast, pancreatic, and prostate carcinomas [77]. Moreover, IL-8 has emerged as a predictive biomarker for resistance to therapies, particularly immunotherapy with checkpoint inhibitors. Patients with high baseline IL-8 levels show diminished responses to anti-PD-1/PD-L1 treatments, likely due to the pre-existing immunosuppressive microenvironment [78].

Therapeutic Targeting Strategies

Given its central role in tumor progression, the IL-8 pathway is an attractive target for cancer therapy. Several strategies are under investigation, including neutralizing antibodies against IL-8 and small-molecule inhibitors of CXCR1 and CXCR2. BMS-986253 (HuMax-IL8), a human monoclonal antibody against IL-8, has shown acceptable safety and dose-dependent suppression of circulating IL-8 in a phase I trial, with some patients achieving stable disease [79]. Reparixin, an oral inhibitor of CXCR1/2, has demonstrated the ability to deplete cancer stem cells and reduce metastasis in preclinical models of breast cancer [80]. Combination approaches, such as pairing IL-8 pathway inhibitors with chemotherapy, radiation therapy, or immunotherapy, are being explored to overcome resistance and enhance therapeutic efficacy [81]. These efforts highlight the potential of targeting the IL-8 axis to remodel the tumor microenvironment and improve outcomes in cancer patients.

IL-8 as a Biomarker in Disease

Interleukin-8 (IL-8), also known as CXCL8, has emerged as a significant biomarker for assessing disease activity, progression, and therapeutic response across a wide spectrum of pathological conditions. Its central role in promoting inflammation, particularly through the recruitment and activation of neutrophils, makes it a sensitive indicator of ongoing immune and inflammatory processes. Elevated levels of IL-8 have been consistently detected in various diseases, positioning it as a valuable tool for both research and potential clinical applications [1].

IL-8 as a Biomarker in Chronic Inflammatory Diseases

In chronic inflammatory conditions, IL-8 serves as a direct reflection of the intensity of the inflammatory response. In bronchopneumopathy chronic obstructive (BPCO), levels of IL-8 are significantly elevated in both serum and exhaled breath condensate, especially during acute exacerbations. Its concentration correlates with the severity of respiratory symptoms such as cough, sputum production, and dyspnea, and is linked to the persistent accumulation of neutrophils and macrophages in lung tissue, which drives tissue damage and mucus hypersecretion [83]. Similarly, in rheumatoid arthritis (RA), high levels of IL-8 are found in synovial fluid and serum, where it fuels the influx of neutrophils into the joint cavity. These neutrophils release proteolytic enzymes and reactive oxygen species, contributing directly to cartilage degradation and bone erosion [84]. The neutrophil-lymphocyte ratio (NLR), which reflects innate immune activity, has been proposed as a prognostic marker for RA disease activity and correlates with IL-8 levels [85].

In inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, IL-8 is produced by intestinal epithelial cells and lamina propria macrophages in response to luminal bacteria and pro-inflammatory cytokines. Its levels in plasma and tissue are markedly increased in active disease and correlate with endoscopic and clinical severity. However, the specificity of serum IL-8 as a systemic biomarker is limited, as circulating levels may not always accurately reflect the localized inflammation in the gut [86]. In psoriasis, IL-8 is involved in the recruitment of neutrophils to the skin, contributing to the formation of Munro's microabscesses, a characteristic histopathological feature. While serum IL-8 levels are elevated in psoriatic patients, their correlation with disease severity, as measured by the Psoriasis Area and Severity Index (PASI), is not always linear, suggesting its primary action is local within the skin lesion [87].

IL-8 as a Prognostic and Predictive Biomarker in Cancer

In the context of oncology, IL-8 has gained prominence as a prognostic biomarker for poor clinical outcomes. Elevated serum and tumor tissue levels of IL-8 are associated with a worse prognosis in various solid tumors, including non-small cell lung cancer, esophageal cancer, pancreatic cancer, and breast cancer [76]. Its role in promoting angiogenesis, metastasis, and tumor microenvironment immunosuppression underpins this association. IL-8 drives the formation of new blood vessels by stimulating endothelial cell proliferation and migration, and it facilitates metastasis by inducing the epithelial-mesenchymal transition (EMT) and the formation of neutrophil extracellular traps (NETs) [67].

Furthermore, IL-8 is emerging as a predictive biomarker for resistance to conventional therapies. High baseline levels of IL-8 are linked to a suboptimal response to anti-TNF-α therapies in IBD and to a poorer response to immunotherapy in cancer. In metastatic cancers, elevated serum IL-8 is associated with reduced progression-free survival (PFS) and overall survival (OS) in patients receiving systemic therapy, including checkpoint inhibitors like anti-PD-1/PD-L1. This is because IL-8 fosters an immunosuppressive microenvironment by recruiting myeloid-derived suppressor cells (MDSCs) and tumor-associated neutrophils (TANs), which inhibit the activity of cytotoxic T cells, thereby blunting the efficacy of immunotherapy [78].

Challenges and Limitations of IL-8 as a Clinical Biomarker

Despite its biological relevance, the clinical translation of IL-8 as a routine biomarker faces several challenges. A major limitation is the lack of standardized reference values and assay methodologies. Unlike well-established markers such as C-reactive protein (CRP), there are no official guidelines for measuring IL-8, and different immunoassay kits can yield variable results, hindering widespread clinical adoption [1]. Additionally, IL-8 exhibits poor specificity, as its levels rise in numerous conditions, including infections, other inflammatory diseases, and various cancers, making it difficult to use for differential diagnosis.

Another significant challenge is the functional redundancy within the cytokine network. IL-8 shares its receptors, CXCR1 and CXCR2, with other ELR+ CXC chemokines like CXCL1, CXCL2, and CXCL5. This redundancy means that blocking IL-8 alone may not be sufficient to inhibit the pro-inflammatory and pro-tumorigenic signals, as other chemokines can compensate. Finally, the predominantly local action of IL-8 means that systemic levels may not accurately mirror the activity of inflammation or cancer at the tissue level, limiting its value as a surrogate marker [87]. Consequently, while IL-8 remains a powerful biomarker in research and clinical trials, its use in routine clinical practice is currently limited, and efforts are focused on incorporating it into multi-analyte biomarker panels to improve its predictive power [93].

Therapeutic Targeting of the IL-8 Pathway

The IL-8/CXCR1/CXCR2 axis has emerged as a compelling therapeutic target in both chronic inflammatory diseases and cancer due to its central role in neutrophil recruitment, activation, and the perpetuation of pathological inflammation and tumor progression. Given that dysregulated IL-8 signaling contributes to tissue damage, immunosuppression, angiogenesis, and metastasis, numerous strategies are being developed to disrupt this pathway at various levels, including neutralizing the chemokine itself or inhibiting its receptors cytokine angiogenesis metastasis.

Inhibition of IL-8 and Its Receptors in Inflammatory Diseases

In chronic inflammatory conditions such as rheumatoid arthritis, inflammatory bowel disease (IBD), and COPD, elevated IL-8 levels drive persistent neutrophil infiltration, leading to tissue destruction. Therapeutic strategies have focused on blocking the interaction between IL-8 and its receptors, CXCR1 and CXCR2. While monoclonal antibodies targeting IL-8 itself, such as humanized anti-IL-8 (HuMax-IL8), have been tested in preclinical and early clinical studies, none have advanced to approval, partly due to the functional redundancy of chemokines in the ELR+ CXC family neutrophil chemokine.

A more promising approach involves the use of small-molecule antagonists of CXCR1 and CXCR2. Reparixin, a non-competitive oral inhibitor of both receptors, has been evaluated in clinical trials for conditions including pancreatic cancer and ischemia-reperfusion injury, with meta-analyses suggesting potential survival benefits in high-risk patients. Similarly, Ladarixin, another dual CXCR1/CXCR2 inhibitor, has shown efficacy in reducing neutrophil recruitment and activation in models of airway inflammation and is under investigation for autoimmune diseases like type 1 diabetes. Other agents, such as AZD5069 (a selective CXCR2 antagonist), have been studied in combination with immunotherapies like anti-PD-L1 in hepatocellular carcinoma, demonstrating synergistic potential in overcoming immunosuppression autoimmune disease immunosuppression.

Targeting the IL-8 Pathway in Cancer

In the context of solid tumors—including those of the lung, colon, and breast—IL-8 plays a multifaceted pro-tumorigenic role by promoting angiogenesis, facilitating metastasis through induction of the epithelial-mesenchymal transition (EMT), and fostering an immunosuppressive microenvironment. High serum or tumor tissue levels of IL-8 are consistently associated with poor prognosis and resistance to conventional therapies, including chemotherapy and immune checkpoint inhibitors (ICIs) such as anti-PD-1/PD-L1 tumor microenvironment epithelial-mesenchymal transition.

One of the most advanced therapeutic candidates is BMS-986253 (HuMax-IL8), a fully human monoclonal antibody that neutralizes IL-8. In a Phase I trial involving patients with metastatic solid tumors, BMS-986253 demonstrated a favorable safety profile and dose-dependent suppression of circulating IL-8 levels. Although objective tumor responses were limited, some patients achieved stable disease, indicating potential disease-stabilizing effects. Notably, ongoing trials are evaluating BMS-986253 in combination with stereotactic body radiotherapy (SBRT) and nivolumab (anti-PD-1) in oligometastatic cancers (NCT04572451), based on the hypothesis that IL-8 blockade can reduce infiltration of immunosuppressive myeloid cells like polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) and enhance T-cell cytotoxicity immunotherapy checkpoint inhibitor.

Overcoming Challenges in Therapeutic Development

Despite the strong biological rationale, several challenges hinder the clinical translation of IL-8 pathway inhibitors. First, the functional redundancy among ELR+ CXC chemokines—such as CXCL1, CXCL2, CXCL5, and CXCL7, which also signal through CXCR2—means that targeting IL-8 alone may be insufficient to block neutrophil recruitment and myeloid cell activation. This has led to a shift toward receptor-level inhibition, particularly of CXCR2, which can block signals from multiple ligands. Second, the pleiotropic effects of IL-8 across different cell types—including tumor cells, endothelial cells, and immune cells—complicate the prediction of therapeutic outcomes and potential off-target effects cell signaling receptor.

Furthermore, IL-8 is not specific to cancer or inflammation; its levels rise in response to infection, trauma, and other stressors, limiting its utility as a standalone diagnostic or prognostic biomarker. To address this, researchers are exploring multimodal strategies, such as combining IL-8 pathway inhibitors with existing therapies (e.g., chemotherapy, radiation, or ICIs) or using IL-8 as part of a broader biomarker panel that includes IL-6, VEGF, and the neutrophil-to-lymphocyte ratio (NLR) to improve patient stratification and treatment monitoring biomarker precision medicine.

Emerging Molecular Pathways and Future Directions

The pro-tumoral effects of IL-8 are mediated through key intracellular signaling pathways, including NF-κB, PI3K/AKT, and MAPK/ERK, which regulate cell survival, migration, and inflammatory gene expression. Additionally, IL-8 activates FAK, a critical mediator of cell motility and invasion, further supporting its role in metastasis. These pathways represent potential secondary targets for combination therapies aimed at disrupting the full spectrum of IL-8-driven tumor progression signal transduction kinase.

Recent evidence also highlights the importance of feedback loops in the IL-8 network. For instance, IL-8 can activate NF-κB in tumor and stromal cells, which in turn upregulates IL-8 expression, creating a self-amplifying inflammatory circuit. Disrupting this loop—through NF-κB inhibitors or epigenetic modulators—could enhance the efficacy of IL-8-targeted therapies. Moreover, post-translational modifications such as citrullination and proteolytic cleavage by enzymes like neutrophil elastase can generate IL-8 isoforms with altered receptor affinity and biological activity, suggesting that targeting these modifying enzymes might offer an alternative strategy post-translational modification enzyme.

In conclusion, therapeutic targeting of the IL-8 pathway holds significant promise for treating chronic inflammatory diseases and cancers characterized by neutrophil-rich, immunosuppressive microenvironments. While challenges related to redundancy, specificity, and biomarker validation remain, advances in dual receptor inhibition, combination therapies, and multimodal biomarker approaches are paving the way for more effective interventions. Ongoing clinical trials with agents like BMS-986253, reparixin, and SX-682—particularly in combination with immunotherapies—may soon yield breakthroughs in overcoming resistance and improving patient outcomes clinical trial drug development.

References